Lenalidomidefor metastatic renal-cell carcinoma

摘要

"Although lenalidomide seems to have modest activity in advanced kidney cancer, its potential role may be in combination with other novel targeted agents such tyrosine kinase inhibitors", says Matthew Cooney (Case Western Reserve University, Cleveland, OH, USA). Choueiri adds: "This is an active agent, but its development and future in renal-cell carcinoma may take a backseat after the success of novel tyrosine kinase inhibitors".